novo nordisk news - Search News

Novo Nordisk upgraded to Buy from Neutral at UBS

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Business Insider · 1d

Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”

Fintel on MSN · 22h

UBS Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.

Novo Nordisk Expands AI Partnership With Valo Health

MarketWatch on MSN · 1d

Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.

The Wall Street Journal on MSN · 1d

Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact

The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.

DPA International on MSN · 1d

Novo Nordisk expands drug collaboration with Valo Health

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease. It has committed to a near-term payment of $190 million and the collaboration expects milestone payments of approximately $4.

1don MSN

5 Questions Novo Nordisk Needs to Answer to Get Its Stock Moving Higher

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

8hon MSN

Novo, Eli Lilly to dominate global pharma sales in 2025: report

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

1d

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs

Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...

FierceBiotech1d

Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

1d

Novo Nordisk Needs Answers to These 5 Key Questions

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

1d

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

5d

Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

2don MSN

Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results